COMMUNIQUÉS West-GlobeNewswire

BioPorto A/S Appoints Chief Legal Officer
10/04/2024
April 10, 2024 Announcement no. 8 BioPorto A/S Appoints Chief Legal Officer COPENHAGEN, DENMARK and BOSTON, MA, USA, April 10, 2024, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto or Company) (CPH:BIOPOR), an in vitro [...]
Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders
10/04/2024
Vancouver, Canada, April 10, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "company"), a clinical- stage biotech company focused on discovery and development of novel [...]
Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU400—Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication
10/04/2024
MALVERN, Pa., April 10, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, [...]
HOOKIPA Pharma to Host Investor Call on HB-200 and Planned Path to Registration
10/04/2024
HOOKIPA announces alignment with FDA on pivotal trial design and protocol for HB-200 in combination with pembrolizumab HB-200 program receives Priority Medicines (PRIME) designation from EMA NEW YORK and VIENNA, Austria [...]
Interactive Strength Inc. (Nasdaq: TRNR) to Exhibit CLMBR at FIBO Global Fitness, the World's Largest Trade Show for Fitness, Wellness and Health on April 11-14
10/04/2024
FIBO Global Fitness Expects to Have More Than 150,000 Visitors for the Trade Show in Cologne, Germany CLMBR is Receiving Significant Interest From International Boutique Fitness Operators and Gym Chains AUSTIN, TX, [...]
Immuron Travelan® sales continued strong growth
10/04/2024
Sales Highlights: Global FYTD Mar 2024 AUD$3.6 million up 154% on (prior comparative period) pcp Mar 2024 Quarter AUD$1.3 million up 51% on pcp and 75% on last quarter Australia FYTD Mar 2024 AUD$2.8 million up 234% on [...]
Ouma Health reaches milestones in solving maternity care challenges for Managed Care Organizations
10/04/2024
Maternity telehealth platform identifies previously undiagnosed depression in 27% of pregnant & postpartum Medicaid members LOS ANGELES, April 10, 2024 (GLOBE NEWSWIRE) -- Ouma Health, a maternity telehealth company [...]
RadNet to Make its Second Acquisition in Houston, Texas
10/04/2024
LOS ANGELES, April 10, 2024 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective outpatient diagnostic imaging services, today announces that it has signed a [...]
Medicines360 Appoints Erica Rogers to Board of Directors
10/04/2024
Rogers brings over 30 years of experience in the medical technology and healthcare sectors to Medicines360 SAN FRANCISCO, April 10, 2024 (GLOBE NEWSWIRE) -- Medicines360, a global mission-driven women's health company [...]
ViGeneron Announces First Patient Dosed in Phase 1b Clinical Trial of VG901 for the Intravitreal Treatment of Retinitis Pigmentosa
10/04/2024
VG901 is the first and only clinical-stage therapy designed to deliver a functional CNGA1 gene to retinal photoreceptor target cells in retinitis pigmentosa patients VG901, using ViGeneron’s proprietary next-generation [...]
EFA Technologies, pioneer in portable blood labs, enters Brazilian market after Anvisa approval of its portable RevDx device
10/04/2024
efa-technologies.com EFA also secures US $6.5 Million in funding, backed by existing investors and new partners Tel Aviv, Israel, 10 April 2024 - EFA Technologies, pioneers in portable blood labs, today announces the [...]
TILT Biotherapeutics Presents Clinical Data on TILT-123 in Combination with KEYTRUDA® (pembrolizumab) for Ovarian Cancer at AACR 2024
10/04/2024
Results Reveal Mechanism of Action and Correlative Analyses Data HELSINKI, Finland, April 10, 2024 (GLOBE NEWSWIRE) -- TILT Biotherapeutics (TILT), a clinical-stage biotechnology company developing cancer [...]
Philips Respironics reaches agreement with US government on a consent decree creating a clear path forward
10/04/2024
April 10, 2024 Philips confirms that further to communicating the main terms of the Philips Respironics consent decree on January 29, 2024, Philips’ subsidiaries Philips Holding USA and Philips Respironics have now [...]
Recce Pharmaceuticals Selected by UK Government Innovation Agency to Participate in AMR Mission 2024
10/04/2024
Recce recognized by the United Kingdom Government Innovation Agency among the most promising organizations for the UK AMR Inward Mission 2024 Recce chosen as one of 18 organizations globally for its potential to tackle [...]
Mobile-health Network Solutions Announces Pricing of $9 Million Initial Public Offering
10/04/2024
Singapore, April 09, 2024 (GLOBE NEWSWIRE) -- Mobile-health Network Solutions (“ MNDR ” or the “ Company ”), a leading telehealth solutions provider in Singapore, today announced the pricing of its firm commitment [...]
ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”)
09/04/2024
– Twenty patients with indolent (n=18) and aggressive (n=2) R/R B-NHL received evorpacept plus standard rituximab and lenalidomide (“R 2 ”) – Evorpacept plus R 2 was well tolerated with a safety profile similar to [...]
Notable Labs Presents the Design Plan for the PPMP-Enabled Phase 2 Trial with Volasertib for Relapsed/Refractory AML at AACR 2024
09/04/2024
Poster outlines the parameters for developing a flow-cytometry-based PPMP as a companion diagnostic to predict volasertib responders, based on a proof-of-concept study using 41 primary acute myeloid leukemia (AML) [...]
Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting
09/04/2024
Highly selective oral SMARCA2 degrader, PRT7732, shows robust anti-tumor activity in vivo as monotherapy and in combination with chemotherapy, at well-tolerated doses Potentially best-in-class CDK9 inhibitor, PRT2527, [...]
Auron Unveils Preclinical Data Supporting its Lead Program and Ability of its AURIGIN™ Platform to Generate Targeted Cancer Therapies at AACR Annual Meeting
09/04/2024
Preclinical data from lead program addressing AURIGIN-identified KAT2A/B target showed significant cell state shift and tumor growth inhibition across multiple primary cancer models AURIGIN overview highlighted [...]

Pages